Leucovorin Calcium Pentahydrate
Catalog No.S1236 Synonyms: Folinic acid
Molecular Weight(MW): 601.58
Leucovorin is a derivative of folic acid, which can be used to increase levels of folic acid under conditions favoring folic acid inhibition.
Purity & Quality Control
|Description||Leucovorin is a derivative of folic acid, which can be used to increase levels of folic acid under conditions favoring folic acid inhibition.|
Leucovorin administration increases the level of reduced folates in tissues, which promotes the inhibition of thymidylate synthase in two murine colon tumors.  Leucovorin, Gemcitabine, Oxaliplatin, and 5-fluorouracil is a powerful antitumor and immunomodulating regimen that can make the tumor cells a suitable means to induce an Ag-specific CTL response.  Leucovorin (20 mM) increases the cytotoxicity in all three replicate experiments in 10 of the 11 human colorectal carcinoma cell lines.  Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells.  Leucovorin (LV) is a reduced folate cofactor that competes with RTX for transport and polyglutamation in both tumor and normal tissues and thus has potential as a rescue agent. Leucovorin reverses the growth-inhibitory, and potentially cytotoxic, effects of RTX on populations of viable cells. 
|In vivo||Leucovorin (200 mg/kg), which is given after the onset of severe weight loss and diarrhea (twice daily, days 5-7) in mice, prevents further weight loss and induces earlier recovery. Leucovorin (100 or 200 mg/kg; twice daily on days 4-6) reduces the RTX concentration in the liver 2-4-fold on days 7, 9, and 11 compared with controls.  Leucovorin/5-FU and Gastrimmune (200 mg/mL) combinations (12.5 and 20 mg/kg) increase the therapeutic effects on the in vivo growth of DHDK12 tumors when compared to the agents given singly. |
-  Van der Wilt CL, et al. Cancer Res, 1992, 52(18), 4922-4928.
-  Correale P, et al. J Immunol, 2005, 175(2), 820-828.
-  Park JG, et al. J Natl Cancer Inst, 1988, 80(19), 1560-1564.
|In vitro||Water||13 mg/mL warmed (21.6 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04060017||Not yet recruiting||Drug: Levoleucovorin Calcium|Other: Placebo||Autism Spectrum Disorder|Language Disorders||Phoenix Children''s Hospital|State University of New York - Downstate Medical Center|United States Department of Defense|University of Arizona|New York State Institute for Basic Research||December 2019||Phase 2|
|NCT04060030||Not yet recruiting||Drug: Levoleucovorin Calcium|Other: Placebo||Autism Spectrum Disorder|Language Disorders||Phoenix Children''s Hospital|Autism Speaks|State University of New York - Downstate Medical Center|University of Arizona|New York State Institute for Basic Research||December 2019||Phase 2|
|NCT03207724||Recruiting||Drug: Xilonix plus Onivyde and 5FU||Pancreatic Cancer|Cachexia|Weight Loss||Andrew Hendifar MD|Ipsen|XBiotech Inc.|Cedars-Sinai Medical Center||October 16 2017||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.